| abstract |
Formula (I) [Wherein R 1 , R 2 , R 3 , R a , A, B, D and E are all as individually defined. ] And pharmaceutically acceptable salts and solvates thereof. The compounds modify the activity of CFTR and are useful for the treatment of inflammatory or obstructive airway diseases, including, for example, cystic fibrosis, or mucosal hydration. Also described are pharmaceutical compositions containing the present compounds and methods of making the compounds. |